Anticoagulation strategy and safety in critically ill COVID-19 patients: a French retrospective multicentre study.

Autor:	Lamouche-Wilquin, Pauline, Perrin, Léa, Pere, Morgane, Raymond, Matthieu, Asfar, Pierre, Darreau, Cedric, Reizine, Florian, Colin, Gwenhaël, Delbove, Agathe, Auchabie, Johann, Hourmant, Baptiste, Frérou, Aurélien, Combe, Béatrice La, Morin, Jean, Kergoat, Pierre, Lorber, Julien, Egreteau, Pierre-Yves, Souchard, Jérome, Canet, Emmanuel, Lascarrou, Jean-Baptiste
Předmět:	THROMBOEMBOLISM risk factors THROMBOEMBOLISM prevention INTENSIVE care units EVALUATION of medical care LENGTH of stay in hospitals COVID-19 VEINS PULMONARY embolism ADRENOCORTICAL hormones CONFIDENCE intervals ANTICOAGULANTS CRITICALLY ill patient psychology PATIENTS RETROSPECTIVE studies HOSPITAL admission & discharge HOSPITAL mortality VENOUS thrombosis SEVERITY of illness index THROMBOEMBOLISM DESCRIPTIVE statistics RESEARCH funding ODDS ratio PATIENT safety
Zdroj:	Thrombosis Journal; 4/18/2023, Vol. 21 Issue 1, p1-10, 10p
Abstrakt:	Background: Patients with critical illness due to COVID-19 exhibit increased coagulability associated with a high risk of venous thrombo-embolism (VTE). Data on prophylactic anticoagulation for these patients are limited and conflicting. The purpose of this study was to evaluate whether intermediate-dose prophylactic anticoagulation in patients with COVID-19 requiring ICU admission was associated with better outcomes compared to standard-dose prophylactic anticoagulation. Methods: We retrospectively included adults admitted with severe COVID-19 to any of 15 ICUs, in 2020 or 2021. We compared the groups given intermediate-dose vs. standard-dose prophylactic anticoagulation. The primary outcome was all-cause day-90 mortality. Secondary outcomes were VTE (pulmonary embolism or deep vein thrombosis), ICU stay length, and adverse effects of anticoagulation. Results: Of 1174 included patients (mean age, 63 years), 399 received standard-dose and 775 intermediate-dose prophylactic anticoagulation. Of the 211 patients who died within 90 days, 86 (21%) received intermediate and 125 (16%) standard doses. After adjustment on early corticosteroid therapy and critical illness severity, there were no significant between-group differences in day-90 mortality (hazard ratio [HR], 0.73; 95%CI, 0.52–1.04; p = 0.09) or ICU stay length (HR, 0.93; 95%CI, 0.79–1.10; p = 0.38). Intermediate-dose anticoagulation was significantly associated with fewer VTE events (HR, 0.55; 95%CI, 0.38–0.80; p < 0.001). Bleeding events occurred in similar proportions of patients in the two groups (odds ratio, 0.86; 95%CI, 0.50–1.47; p = 0.57). Conclusions: Mortality on day 90 did not differ between the groups given standard-dose and intermediate-dose prophylactic anticoagulation, despite a higher incidence of VTE in the standard-dose group. [ABSTRACT FROM AUTHOR]
Databáze:	Complementary Index
Externí odkaz:	Zobrazit plný text záznamu Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.